After three years, 69% of those taking mitoxantrone had survived, compared with 45% of those given idarubicin.
BBC: Child leukaemia drug boosts survival rates
The study was stopped, and the children taking idarubicin were switched to mitoxantrone.
Children on mitoxantrone also experienced fewer side effects.
应用推荐
模块上移
模块下移
不移动